← Back to Search

Tyrosine Kinase Inhibitor

Erlotinib for Glioblastoma

Phase 2

Waitlist Available

Research Sponsored by The Cleveland Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Previously treated with optimal radiotherapy and at least 1 cytotoxic chemotherapy regimen

Age 18 and over

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well erlotinib works in treating patients with recurrent or progressive glioblastoma multiforme.

Who is the study for?

This trial is for adults with glioblastoma multiforme that has come back or gotten worse. They should have already tried radiotherapy and chemotherapy, be able to take pills, not pregnant/nursing, use birth control if they can have kids, and have no other serious medical issues or infections.Check my eligibility

What is being tested?

The trial is testing Erlotinib's ability to block enzymes that help cancer cells grow in patients with recurrent or progressive glioblastoma multiforme. It's a Phase II study which means it focuses on the drug’s effectiveness.See study design

What are the potential side effects?

Erlotinib may cause side effects like rash, diarrhea, loss of appetite, fatigue, difficulty breathing and coughing. Liver function might also be affected leading to increased liver enzymes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I've had radiation and at least one chemotherapy treatment before.

Select...

I am 18 years old or older.

Select...

My bilirubin levels are not more than twice the normal range.

Select...

I have been diagnosed with glioblastoma multiforme.

Select...

I do not have any current infections.

Select...

My cancer has shown signs of growing or coming back on scans.

Select...

I can take medications by mouth without any issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response rate

Secondary outcome measures

Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling

Efficacy of tumor EGFR amplification in predicting response to treatment

Overall survival

+1 more

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor

1,030 Previous Clinical Trials

1,363,945 Total Patients Enrolled

Michael A. Vogelbaum, MD, PhDStudy ChairThe Cleveland Clinic

4 Previous Clinical Trials

803 Total Patients Enrolled

Media Library

Erlotinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00054496 — Phase 2

Brain Tumor Clinical Trial 2023: Erlotinib Highlights & Side Effects. Trial Name: NCT00054496 — Phase 2

Erlotinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00054496 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risk factors should be considered when evaluating this treatment?

"Drawing on available data, our team at Power has assigned a score of 2 in terms of safety to this treatment. This is due to it being part of Phase 2 trials which have some clinical evidence attesting its security but none affirming efficacy."

Answered by AI

Are there opportunities for participants to enroll in this experiment?

"Clinicaltrials.gov reveals that this clinical trial has ceased to recruit participants, having been first posted on August 1st 2002 and most recently updated January 9th 2014. Luckily, there are 544 other studies actively seeking enrolment now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

2002. "Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00054496.

All > Gbm > Paid Studies Ohio